Portal Vein Thrombosis Clinical Trial
Official title:
Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Treatment Combined With Propranolol for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial
Portal vein thrombosis (PVT) refers to an obstruction in the trunk of the portal vein. It
can extend downstream to the portal branches, or upstream to the splenic and/or the
mesenteric veins. The prevalence of PVT is 10-25% and incidence is about 16% in cirrhotic
patients. Recent studies demonstrate that the presence of PVT is not only an independent
predictor of failure to control active variceal bleeding and prevent variceal rebleeding,
but also significantly associated with increased mortality in patients with liver cirrhosis.
However, in recent American Association of the Study of Liver Disease (AASLD) practice
guidelines and Baveno V consensus, no treatment strategies in cirrhotic patients with PVT
was clearly recommended due to the absence of randomized controlled trials.
Usually, cirrhotic patients with PVT are submitted to variceal rebleeding prophylaxis with
endoscopic band ligation combined with non-selective beta-blockers and, when necessary, the
anticoagulation is started after the varices eradication.
TIPS is just regarded as the second-line therapy for the secondary prophylaxis of variceal
bleeding in cirrhotic patients. However, this indication might be changed in the setting of
PVT. Indeed, the risk to benefit ratio of TIPS in cirrhotic patients with PVT for the
prevention of recurrent variceal bleeding has never been evaluated.
The aim of this study is to compare the efficacy and safety of TIPS and endoscopic band
ligation + propranolol in decompensated cirrhosis patients with PVT and a history of
variceal bleeding in the past 6 weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03631147 -
The Effect of Rifaximin on Portal Vein Thrombosis
|
N/A | |
Completed |
NCT02250391 -
Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis
|
Phase 3 | |
Recruiting |
NCT05625893 -
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion
|
Phase 2 | |
Completed |
NCT05012501 -
Analysis of Neutrophil Extracellular Traps in Hypercoagulability and Portal Vein Thrombosis in Liver Cirrhosis Patients
|
||
Terminated |
NCT00769873 -
Anticoagulation Post Laparoscopic Splenectomy
|
Phase 2 | |
Recruiting |
NCT05123326 -
Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome
|
||
Completed |
NCT01095185 -
Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding
|
Phase 3 | |
Completed |
NCT02585713 -
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
|
Phase 3 | |
Not yet recruiting |
NCT06117488 -
Risk Factors and Management Outcome of Chronic Portal Vein Thrombosis in Children
|
||
Not yet recruiting |
NCT05339581 -
IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation
|
N/A | |
Recruiting |
NCT03902678 -
Role of EUS Guided FNA of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma
|
N/A | |
Not yet recruiting |
NCT06319131 -
Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT
|
N/A | |
Recruiting |
NCT03193502 -
Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis
|
Phase 3 | |
Completed |
NCT03201367 -
Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV
|
N/A | |
Completed |
NCT03477149 -
EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications
|
N/A | |
Recruiting |
NCT02398357 -
The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis
|
Phase 4 | |
Completed |
NCT01556282 -
TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis
|
N/A | |
Withdrawn |
NCT01631877 -
Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver
|
N/A | |
Recruiting |
NCT04433481 -
Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis
|
N/A | |
Not yet recruiting |
NCT05872841 -
H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis
|
Phase 2 |